Stock Events

Sosei 

$8.72
3
+$0+0% Friday 14:30

Statistics

Day High
9.5
Day Low
9.5
52W High
22.78
52W Low
8.93
Volume
500
Avg. Volume
184
Mkt Cap
1.27B
P/E Ratio
0
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

10NovConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-25.39
-7.52
10.34
28.21
Expected EPS
N/A
Actual EPS
3.82

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SOLTF. It's not an investment recommendation.

About

Pharmaceuticals: Generic
Health Technology
Sosei Group Corporation develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Sosei Group Corporation was incorporated in 1990 and is headquartered in Tokyo, Japan.
Show more...
CEO
Mr. Shinichi Tamura
Employees
350
Country
JP
ISIN
JP3431300007
WKN
000A0B7EK

Listings